

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 December 2023 (07.12.2023)



(10) International Publication Number
WO 2023/235360 A1

(51) International Patent Classification:

A61P 25/28 (2006.01) A61K 38/10 (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2023/023937

(22) International Filing Date:

31 May 2023 (31.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/347,073	31 May 2022 (31.05.2022)	US
63/413,430	05 October 2022 (05.10.2022)	US
63/478,330	03 January 2023 (03.01.2023)	US
63/478,336	03 January 2023 (03.01.2023)	US

(71) Applicant: **BIOAGE LABS, INC.** [US/US]; 1445A S 50th St., Richmond, CA 94804 (US).

(72) Inventors: **REBO, Justin**; BioAge Labs, Inc., 1445A S 50th St., Richmond, CA 94804 (US). **WANG, Yan**; BioAge Labs, Inc., 1445A S 50th St., Richmond, CA 94804 (US). **LUNDQUIST, Adam**; BioAge Labs, Inc., 1445A S 50th St., Richmond, CA 94804 (US). **BANICKI, Matthew**; BioAge Labs, Inc., 1445A S 50th St., Richmond, CA 94804 (US). **HUGHES, Robert**; BioAge Labs, Inc., 1445A S 50th St., Richmond, CA 94804 (US). **LEONG, Peng, Khun**; BioAge Labs, Inc., 1445A S 50th St., Richmond, CA 94804 (US).

(74) Agent: **SEQUEIRA, Antonia, L.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

(54) Title: APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY




FIG. 4C

(57) Abstract: This disclosure provides methods for using a particular class of apelin receptor modulators to reduce blood-brain barrier (BBB) permeability in a subject in need thereof, and in particular methods of treatment for a variety of disorders, conditions, and diseases associated with and related to increased BBB permeability. This disclosure also provides methods for using a particular class of apelin receptor modulators to treat a neurodegenerative disease, delirium, and/or dementia in a subject in need thereof. This disclosure also provides methods for using a particular class of apelin receptor modulators to reduce neuroinflammation in a subject in need thereof. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.

[Continued on next page]

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*